Journal
CHEMICAL BIOLOGY & DRUG DESIGN
Volume 81, Issue 1, Pages 13-21Publisher
WILEY
DOI: 10.1111/cbdd.12045
Keywords
ADAR; Ca(V)1.3; CDAR; GABA receptor; glutamate receptor; glycine receptor; Kv1.1; RNA editing; serotonin receptor
Funding
- P.E. Kempkes foundation Marburg
Ask authors/readers for more resources
Virtually all organisms use RNA editing as a powerful post-transcriptional mechanism to recode genomic information and to increase functional protein diversity. The enzymatic editing of pre-mRNA by ADARs and CDARs is known to change the functional properties of neuronal receptors and ion channels regulating cellular excitability. However, RNA editing is also an important mechanism for genes expressed outside the brain. The fact that RNA editing breaks the one gene encodes one protein hypothesis is daunting for scientists and a probable drawback for drug development, as scientists might search for drugs targeting the wrong protein. This possible difficulty for drug discovery and development became more evident from recent publications, describing that RNA editing events have profound impact on the pharmacology of some common drug targets. These recent studies highlight that RNA editing can cause massive discrepancies between the in vitro and in vivo pharmacology. Here, we review the putative impact of RNA editing on drug discovery, as RNA editing has to be considered before using high-throughput screens, rational drug design or choosing the right model organism for target validation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available